Intuitive Surgical (NASDAQ:ISRG) Hits New 12-Month High on Analyst Upgrade

Intuitive Surgical, Inc. (NASDAQ:ISRG)’s stock price reached a new 52-week high on Tuesday after Evercore ISI raised their price target on the stock from $410.00 to $475.00. Evercore ISI currently has an in-line rating on the stock. Intuitive Surgical traded as high as $496.48 and last traded at $486.17, with a volume of 179159 shares traded. The stock had previously closed at $491.27.

Several other research firms also recently weighed in on ISRG. Citigroup lifted their price objective on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. JPMorgan Chase & Co. lifted their price objective on Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Truist Financial lifted their price objective on Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a report on Tuesday, July 16th. BTIG Research lifted their price objective on Intuitive Surgical from $469.00 to $494.00 and gave the company a “buy” rating in a report on Wednesday, August 28th. Finally, Piper Sandler lifted their price objective on Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $449.70.

Insider Transactions at Intuitive Surgical

In other news, Director Amal M. Johnson sold 2,943 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the sale, the director now owns 12,275 shares in the company, valued at $5,441,507.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the sale, the senior vice president now owns 3,001 shares in the company, valued at $1,461,006.84. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Amal M. Johnson sold 2,943 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the sale, the director now owns 12,275 shares in the company, valued at approximately $5,441,507.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 53,120 shares of company stock worth $25,528,753. Insiders own 0.90% of the company’s stock.

Institutional Investors Weigh In On Intuitive Surgical

A number of large investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Intuitive Surgical by 1.6% in the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after buying an additional 493,126 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Intuitive Surgical by 1.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock worth $5,726,102,000 after purchasing an additional 272,741 shares in the last quarter. Capital World Investors boosted its position in Intuitive Surgical by 1.0% in the 1st quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock worth $2,907,079,000 after purchasing an additional 73,634 shares in the last quarter. Jennison Associates LLC boosted its position in Intuitive Surgical by 4.6% in the 1st quarter. Jennison Associates LLC now owns 4,488,343 shares of the medical equipment provider’s stock worth $1,791,253,000 after purchasing an additional 198,483 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its position in Intuitive Surgical by 1.9% in the 4th quarter. Fisher Asset Management LLC now owns 4,488,048 shares of the medical equipment provider’s stock worth $1,514,088,000 after purchasing an additional 82,652 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Trading Down 1.3 %

The company has a 50-day simple moving average of $474.22 and a 200 day simple moving average of $430.19. The firm has a market cap of $171.94 billion, a PE ratio of 87.50, a price-to-earnings-growth ratio of 5.39 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same quarter in the prior year, the firm posted $1.18 EPS. The business’s quarterly revenue was up 14.5% compared to the same quarter last year. On average, equities analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.